Drugs / Claudin18.2 Targeted CAR-T Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07416240 | Feb 2026 → Feb 2028 expected | pancreatic neoplasm | Hainan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06946615 | Apr 2025 → Apr 2026 overdue | colorectal neoplasm | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Claudin18.2 Targeted CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07416240 ↗ |
| Action | Deplete | “precisely and persistently killing cancer cells” NCT07416240 ↗ |
| Modality | Cell therapy | “Autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting Claudin18.2.” NCT06946615 ↗ |